Taking into account that most of HER2-positive GC originates from the gastroesophageal junction (GEJ) and that these tumors have been historically treated with neoadjuvant chemoradiotherapy as an alternative to perioperative chemotherapy, the targeting of HER2 has been investigated also in combination with the CROSS regimen. Here, ERBB2 is linked to gastric cancer.